Aigen Investment Management LP Invests $1.55 Million in IQVIA Holdings Inc. (NYSE:IQV)

Aigen Investment Management LP purchased a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) during the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 7,873 shares of the medical research company’s stock, valued at approximately $1,547,000.

Several other institutional investors have also recently added to or reduced their stakes in IQV. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter valued at approximately $27,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Synergy Asset Management LLC purchased a new position in IQVIA in the 4th quarter valued at $33,000. Assetmark Inc. increased its stake in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC purchased a new position in IQVIA during the 3rd quarter worth $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. dropped their price target on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Truist Financial reiterated a “buy” rating and set a $263.00 target price (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Performance

IQVIA stock opened at $183.75 on Wednesday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $261.73. The stock has a fifty day moving average of $198.52 and a two-hundred day moving average of $213.86. The company has a market capitalization of $32.36 billion, a price-to-earnings ratio of 24.50, a PEG ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.